Brussels: The European Union is committing £225 million to speed up the development of next-generation flu vaccines that will offer protection across a wider range of influenza variants and quickly adapted if a pandemic strain emerges. It marks the first time the European Commission will be using pre-commercial procurement to advance products through clinical trials, ensuring they meet strict safety, quality, and efficacy criteria while supporting innovations that might otherwise stall without public intervention.
According to Emirates News Agency, the funding will support vaccines designed to be easier to administer via the nose, mouth, or skin patches and rapidly scaled up in emergencies. Commissioner for Equality, Preparedness, and Crisis Management, Hadja Lahbib, emphasized the significance of the investment, stating it is the largest ever dedicated to accelerating access to innovative medical countermeasures. Lahbib noted that such funding would unlock cutting-edge technologies, including more accessible vaccine administration methods, ensuring that effective vaccine options reach underserved and vulnerable groups. This investment is also poised to strengthen Europe's pharmaceutical ecosystem, enhancing its competitiveness and reinforcing resilience against future health threats.
Through the full clinical development of promising vaccine candidates, the EU aims to widen the pipeline, enabling more products to be in development. This initiative intends to ensure that new solutions can be integrated into national vaccination programs more swiftly, providing patient-friendly vaccines to help countries respond with greater speed and coordination when outbreaks intensify.
The contracts signed under this initiative will run for 98 months, covering clinical development through to market authorization.